Kornimate/medical-research-clean huggingface dataset:
is lymphocyte subtype important for acute pancreatitis severity?

Conditions: Pancreatitis; Lymphocytic Infiltrate; Immune System Diseases

Summary: pancreatitis is a common complication especially in patients with gallbladder stones, most patients with biliary pancreatitis may recover spontaneously without sequelae, but in 10-20% of patients, the disease is severe and mortality rates of up to 30% are detected in these patients. in the evaluation of acute biliary pancreatitis, many scoring systems have been established (atlanta, ranson, apache, bisap etc.) from past to present to determine morbidity and mortality of the disease. in this study, the investigators aimed to evaluate the correlation between morbidity and mortality of acute biliary pancreatitis and lymphocyte subtypes with flow-cytometry.

pancreatitis is a common complication especially in patients with gallbladder stones, most patients with biliary pancreatitis may recover spontaneously without sequelae, but in 10-20% of patients, the disease is severe and mortality rates of up to 30% are detected in these patients. in patients with severe pancreatitis, aggressive fluid replacement, organ damage follow-up, appropriate antibiotherapy, and endoscopic sphincterotomy and radiological interventions may be of great benefit. in the evaluation of acute biliary pancreatitis, many scoring systems have been established (atlanta, ranson, apache, bisap etc.) from past to present to determine morbidity and mortality of the disease. there are limited number of studies in the literature about the immune parameters in the evaluation of acute pancreatitis. in a studies, serum inflammatory markers such as il-1, il-6 and cd4, cd8 t lymphocyte and treg population were evaluated.treg cells are reported to be an independent prognostic factor in determining the severity of acute pancreatitis. in patients diagnosed with acute biliary pancreatitis, determination of the course of the disease at the time of diagnosis is extremely important for treatment and survival. in this study, the investigators aimed to evaluate the correlation between morbidity and mortality of acute biliary pancreatitis with lymphocyte subtypes via flow-cytometry.

Eligibility criteria:
inclusion criteria: * 18-80 years old * diagnosis of acute biliary pancreatitis * sign the voluntary consent form exclusion criteria: * being under 18 or older than 80 * not signing the voluntary consent form * pancreatitis resulting from an interventional procedure (ercp, surgery, etc.) * pregnant women * being a history of immunodeficiency * cancer history

Keywords: pancreatitis lymphocyte flow-cytometry
a retrospective analysis of outcomes in patients with hepatorenal syndrome at methodist dallas medical center

Conditions: Hepatorenal Syndrome

Summary: hepatorenal syndrome (hrs) is a common cause of acute kidney injury (aki) in patients with liver disease \[1\]. increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. patients may present with elevated serum creatinine (cr), benign urine sediment, and low urine sodium \[1\].

there are two main classifications of hrs: hrs-aki (previously known as type 1 hrs) and diuretic-resistant ascites (previously known as type 2 hrs) \[1\]. the ultimate treatment for patients with hrs is to improve hepatic function via treatment of underlying etiology or liver transplantation; however, this is not always immediately possible due to the high demand for liver transplantation among other factors \[1\]. continuous renal replacement therapy (crrt) can also be considered, especially in patients with severe electrolyte derangements such as hypokalemia or pulmonary edema, that are not responding to medical therapy \[1\]. often, crrt is used as a bridging therapy to stabilize patients until they are optimized for receiving a liver transplant \[1, 2\]. crrt, however, comes with its own risks and disadvantages such as hypotension and increased risk of cardiac adverse events \[2\]. in certain cases, transjugular intrahepatic portosystemic shunts (tips) can benefit patients with hrs by reducing portal pressure resulting in increase in renal perfusion \[1\].

Eligibility criteria:
inclusion criteria: * all patients \>18 years old that were hospitalized between april 1st 2019 and april 1st 2023 who either presented with hrs-aki or developed a diagnosis of hrs during the hospital course. hrs-aki will be defined based on the ica criteria, described below: 1. presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure 2. an increase in serum cr of ≥0.3 mg/dl within 48 hours or ≥50% from baseline value and/or urinary output ≤0.5 ml/kg of body weight for ≥6 hours (requires use of a urinary catheter) 3. no full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g/kg of body weight/day) 4. absence of shock 5. no current or recent treatment with nephrotoxic drugs 6. absence of parenchymal renal disease 7. suggestion of renal vasoconstriction based on fena \<0.2% exclusion criteria: * 1. hrs-aki patients \<18 years of age 2. all patients hospitalized between april 1st 2019 and april 1st 2023 without a diagnosis of hrs-aki.
protein expression in tumor tissue samples from patients with cancer of the oropharynx

Conditions: Head and Neck Cancer

Summary: rationale: studying the proteins expressed in samples of tumor tissue from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors plan better treatment for patients with cancer of the oropharynx. purpose: this laboratory study is looking at protein expression in tumor tissue samples from patients with cancer of the oropharynx.

objectives: * to investigate if some of the differences in gene expression are also reflected at the protein level. * to determine whether differences in gene expression that are also reflected at the protein level can be used to develop markers for early detection and disease surveillance. * to identify targets for therapy. outline: archived tumor tissue samples are analyzed for expression of standard immunohistological markers (e.g., p16, p53, and ki-67) as well as expression of genes identified in a previous gene expression study. protein expression data are tested for clinical and demographic correlates and compared with gene expression data.

Eligibility criteria:
inclusion criteria: * diagnosis of squamous cell carcinoma of the oropharynx * tumor tissue samples available from vanderbilt head and neck tumor repository and vanderbilt pathology archives exclusion criteria: * not specified prior concurrent therapy: * not specified

Keywords: recurrent squamous cell carcinoma of the oropharynx stage i squamous cell carcinoma of the oropharynx stage ii squamous cell carcinoma of the oropharynx stage iii squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the oropharynx
uterine rupture after hysteroscopic septum resection

Conditions: Septum; Uterus; Rupture, Uterine

Summary: to date, several studies have already confirmed a positive effect of hysteroscopic metroplasty on reproductive outcomes in primary infertile women affected by uterine septum, the most common uterine malformation. nevertheless, very few data are available about the risk of uterine rupture in subsequent pregnancies after hysteroscopic septum resection (hsr). in order to shed about this element, we will retrospectively review the cases of uterine rupture in our setting in the last twenty years, identify which of them had previously undergone hsr, and evaluate the main clinical characteristics for each case.


Eligibility criteria:
inclusion criteria: * previous hysteroscopic septum resection; * pregnancy; * uterine rupture. exclusion criteria: * previous myomectomy (regardless of the surgical technique) or cesarean section.

Keywords: hysteroscopy uterine septum complications uterine perforation pregnancy uterine rupture
investigation from biopsychosocial perspective of patients with rheumatic disease with covid-19 who participated in a biopsychosocial exercise program: a case series with 6-month follow-up

Conditions: Rheumatic Diseases

Summary: objective: this novel study aimed to interrogate from a biopsychosocial perspective the health conditions during the covid-19 infection and long-covid periods of 5 patients with rheumatic disease infected with covid-19 who had acquired the habit of regular exercise before the pandemic. method: this case study included five patients suffering from covid-19 infection among patients with rheumatic disease who had acquired the habit of regular exercise before the covid-19 pandemic. it was applied a questionnaire to the patients from a biopsychosocial perspective to see the short and long-term effects of covid-19 during and after quarantine. moreover, the study used the bety-biopsychosocical questionnaire (bety-bq) to evaluate a biopsychosocial point, health assessment questionnaire (haq) to measure functional status, and the hospital anxiety and depression scale (hads) to assess anxiety and depression. results: in bety-bq, haq, and hads, there was an unfavorable increase in overall scores of all patients during covid-19. after six months, although the results from these three scales improved, some of the patients could not return to their pre-covid state. conclusions: the patients participating in the telerehabilitation were able to return to everyday life after covid more efficiently and overcome post-covid symptoms easily. this study is important in guiding the exercise approach for patients with rheumatic diseases in pandemics such as covid-19.


Eligibility criteria:
inclusion criteria: * patients with the rheumatic disease passed for at least six months after their covid-19 infection between the ages of 18-65 were included in the study. exclusion criteria: * exclusion criteria were the presence of deformity that does not allow exercise, cardiopulmonary disorders, uncontrolled endocrine system diseases, severe psychiatric illnesses, and insufficient skills in using a smartphone.

Keywords: cognitive exercise therapy approach biopsychosocial exercise rheumatology rehabilitation qualitative research case report
mindfulness-based cognitive therapy + safety planning for suicidal behavior

Conditions: Monopolar Depression, Single Episode or Unspecified; Suicidal and Self-injurious Behaviour

Summary: the purpose of this study is to combine and adapt mindfulness-based cognitive therapy (mbct) + safety planning intervention (spi) for individuals with suicidal behavior and to determine its feasibility, acceptability, safety and preliminary effectiveness. an exploratory aim is to collect data on the cognitive changes underlying treatment gains.

* the study is a nine-week clinical trial combining safety planning intervention plus mindfulness-based cognitive therapy for patients with a recent history of suicidal thoughts or behavior and current or past depressive symptoms. * these treatments work for depression and some preliminary data suggest they may work to prevent suicidal behavior. * participation includes: * nine weeks of free treatment * clinical assessments * an opportunity to offer your views on treatment and suggestions for improving the treatment in focus groups

Eligibility criteria:
inclusion criteria: * 18-65 * history of depression * suicidal behavior or thoughts (i.e., current suicidal thoughts at screening and history of at least one suicide attempt or suicide-related behavior (aborted or interrupted suicide attempt) or suicidal ideation with plan or method in the past 6 months) * in active treatment (e.g., receiving psychiatric medications) exclusion criteria: * current mania, psychosis, obsessive-compulsive disorder, traumatic brain damage, organic or acute brain syndrome, mental retardation or pervasive developmental disorder * requires priority treatment for an acute illness or debilitating problem such as severe primary substance dependence or anorexia nervosa * inability to complete psychiatric interview or group treatment due to lack of cooperation or lack of comprehension.
effect of bm-mscs on chronic amr after kidney transplantation

Conditions: Kidney Transplantation

Summary: this study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (bm-mscs) on chronic antibody-mediated rejection (camr) after kidney transplantation. chronic amr is diagnosed according to banff criteria 2013 based on renal graft biopsy and donor specific antibodies (dsa) examination. camr patients are assigned to mscs group or control group. patients in control group are prescribed to current desensitization therapy including at least one of the following treatments: plasmapheresis (pp), intravenous immunoglobulin (ivig), rituximab or bortezomib, depending on individual pathological and immunological features (eg. dsa type and titer) of each study subjects. patients in mscs group receive additional bm-mscs therapy besides desensitization treatments as in control group. allogeneic bm-mscs (1\*10\^6/kg) are intravenously administered every two weeks for four consecutive doses. all camr patients are followed up for one year. renal function, dsa level, pathological features, patient/graft survival, and severe adverse events are monitored during the follow-up period. immunological features of patients in both groups are consecutively examined.


Eligibility criteria:
inclusion criteria: * kidney transplantation * camr diagnosis is determined based on renal graft biopsy and dsa examination * patient is willing and capable of giving written informed consent for study participation and able to participate in the study for 12 months exclusion criteria: * combined or multi-organ transplantation * women who are pregnant, intend to become pregnant in the next 1 years, breastfeeding, or have a positive pregnancy test on enrollment or prior to study medication administration * donors or recipients are known hepatitis c antibody-positive or polymerase chain reaction (pcr) positive for hepatitis c * donors or recipients are known hepatitis b surface antigen-positive or pcr positive for hepatitis b * donors or recipients are known human immunodeficiency virus (hiv) infection * patients with active infection * recipients with a history of substance abuse (drugs or alcohol) within the past 6 months, or psychotic disorders that are not capable with adequate study follow- up * patients with severe cardiovascular dysfunction * wbc\<3\*10\^9/l or rbc \<5g/dl * highly allergic constitution or having severe history of allergies * patients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal problem affect absorption * patients with a history of cancer within the last 5 years * prisoner or patients compulsorily detained (involuntarily incarcerated) for treatment or either a psychiatric or physical (e.g. infectious disease) illness * renal graft function deteriorates due to non-immunological complication, such as surgical issues or drug nephrotoxicity

Keywords: kidney transplantation antibody-mediated rejection mesenchymal stem cell therapy donor specific antibody acute rejection
efficacy, safety and tolerability of ain457 in moderate to severe active crohn's disease

Conditions: Crohn's Disease

Summary: this study will assess the safety and efficacy of ain457 in patients with moderate to severe active crohn's disease.


Eligibility criteria:
inclusion criteria: * male or female; 18-75 years old * diagnosis of crohn's disease for at least 3 months prior to screening * confirmation of crohn's disease by endoscopic or imaging examination * moderately active crohn's disease at baseline, defined as: * cdai ≥220 and ≤450 * active disease despite prior treatment with corticosteroids for at least 2 weeks, or immunosuppressants for at least 3 months. treatment with azathioprine, 6-mp or mtx is allowed but must have been on a stable dose for at least 10 weeks, corticosteroids are allowed but must have been on a stable doses of prednisolone not exceeding 40 mg for two weeks prior to baseline. immunosuppressants other than those listed above, such as cyclosporine, tacrolimus and mycophenolate, are not allowed and must be stopped (wash-out periods defined in the protocol); exclusion criteria: * body mass index \>34 * positive ppd tuberculin skin test or quantiferon test * any subject with evidence of active pulmonary disease or evidence of latent tuberculosis or fungal infection at screening or within past 3 months * symptoms associated with active bowel structuring disease and pre-stenotic dilation on radiographs * fistulizing disease if complicated by sepsis and/or untreated abscess * multiple bowel surgeries and clinically important short bowel syndrome defined as an inability to maintain caloric intake * use of certain medications as specified in the protocol * clinical improvement due to other crohn's therapy other protocol-defined inclusion/exclusion criteria may apply

Keywords: crohn's disease, moderate, severe, active, ain457
the value of placental vascularization and placental volume in pregnancy in apls

Conditions: Antiphospholipid Syndrome in Pregnancy

Summary: antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. among these groups of antibodies, lupus anticoagulant (la) and anticardiolipin antibodies (acl)

apls can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (sle) in a 40% of the cases.

Eligibility criteria:
inclusion criteria: * singleton pregnancy. * gestational age of 34-37 weeks. * pregnant women with antiphospholipid syndrome exclusion criteria: * twin or multiple pregnancies. * congenital fetal anomalies. * gestational age of less than 34. * gestational age of more than 37. * women with placental or umbilical artery anomalies. * antepartum hemorrhage (placental abruption, placenta previa and vasa previa). * posterior placenta. * history of rupture of membrane. * patient refusal or fall outs.
anti-sars-cov-2 inactivated convalescent plasma in the treatment of covid-19

Conditions: Coronavirus

Summary: there is still no effective antiviral drugs and vaccines against sars-cov-2 yet now. this is an obsevational study, the investigators collected the clinical information and clinical outcomes of the covid-19 patients using anti-2019-ncov inactivated convalescent plasma.the study is to evaluate the efficacy and safety of anti-2019-ncov inactivated convalescent plasma in the treatment of covid-19 pneumonia.


Eligibility criteria:
inclusion criteria: * the participants were diagnosed as covid-19; * participants received anti-sars-cov-2 inactivated convalescent plasma * written the informed consent. exclusion criteria: * participants lacked detailed medical history

Keywords: plasma transfusion coronavirus
a study to evaluate the real-world effectiveness and usage of alprolix in patients with haemophilia b in france

Conditions: Haemophilia B

Summary: alprolix (rfixfc) is a recombinant extended half-life coagulation factor product. the purpose of this non-interventional study is to describe the real-world usage and effectiveness of alprolix in the on-demand and prophylactic treatment of haemophilia b.


Eligibility criteria:
inclusion criteria: * have a diagnosis of haemophilia b and been treated previously with factor ix product * have started alprolix treatment prior to enrolment visit, or at enrolment prescribed treatment with alprolix, regardless of participation in the study * signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, before any study-related activities are undertaken. assent should be obtained from paediatric patients according to local regulations exclusion criteria: * participation in an investigational medicinal product trial at enrolment visit

Keywords: blood coagulation disorder hematologic diseases coagulation protein disorder hemorrhagic disorder genetic diseases, inborn
prognostic factors associated with postoperative cognitive dysfunction after surgery

Conditions: Postoperative Cognitive Dysfunction

Summary: a longitudinal observational study examining preoperative, intraoperative and postoperative factors associated with postoperative cognitive dysfunction in patients older than the age of 50.

a longitudinal observational study examining factors associated with postoperative cognitive dysfunction (pocd) utilizing a computerized neurocognitive battery. in addition, investigators seek to assess the presence of pre-existing psychiatric disorders and chronic pain to determine their relationship with pocd. the study will seek to compare the rates of pocd in previously published literature with performance on a computerized neurocognitive battery. in addition, the study will seek to determine preoperative, intraoperative and postoperative factors associated with pocd by comparing these variables to performance on a computerized neurocognitive battery.

Eligibility criteria:
inclusion criteria: 1. ability to perform informed consent 2. age greater than 50 years old 3. ability to read and understand english 4. undergoing elective surgery with general or neuraxial anesthesia exclusion criteria: 1. patients who do not meet above defined criteria, patients from vulnerable populations (adults unable to consent, pregnant women, prisoners), patients refusing informed consent and participation in the study. 2. a previous history of the following medical conditions: dementia of any kind (vascular dementia, alzheimer's disease, organic brain disease with documented cognitive deficits, severe traumatic brain injury, parkinson's disease, senility) 3. physical impairment impairing their ability to perform neurocognitive testing incl. essential tremor, loss of upper extremity motor function, blindness, or severe hearing loss)